Health Care Delivery

To conclude our interview with him, Ravin Ratan, MD, MEd, of MD Anderson, explains the importance of caring for all patients and why he tries to own the process of patients feeling confident that they received the attention they deserve.

AJMC's Center on Health Equity & Access shares new developments in HIV treatment, gynecological and multidisciplinary cancer care, and health care barriers faced by older Americans.

Low-value service utilization is common among all older adults, and utilization of some high-value services decreases after the onset of cognitive decline.

In our ongoing interview with Jessica K. Paulus, ScD, Ontada, she explains potential drivers behind changing trends in care for lung cancer that may have been influenced by the COVID-19 pandemic.

Investigators compared cost-effectiveness of the KRAS inhibitor sotorasib against the taxane docetaxel in the second line for non–small cell lung cancer (NSCLC).

Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network, breaks down the causes of the ongoing cancer drug shortage, as well as its impact on clinical trials.

Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, discusses the hopeful future of treatment in idiopathic hypersomnia.

Sindhuja Kadambi, MD, MS, University of Rochester Medical Center, discussed in detail the unique considerations necessary for oncology care in the aging population.

The FIREFISH study showed that most children with type I spinal muscular atrophy (SMA) maintained or improved motor functions and feeding abilities over 5 years when treated with risdiplam.

Dedifferentiated liposarcoma is a fast-growing and more aggressive type of soft tissue sarcoma that originates as a well-differentiated sarcoma and has a typical diagnosis age of 40 to 60 years.

Minority patients with gynecologic cancers are more likely than White patients to receive treatment at academic facilities, a recent study found.

Liz Kwo, MD, MBA, MPH, chief commercial officer, Everly Health, and faculty lecturer, Harvard Medical School, shares important tips on how artificial intelligence (AI) can best be implemented into value-based care.

Insurers continue to raise consumer costs despite covering fewer drugs and having more drug coverage restrictions; the Biden Administration is investing hundreds of millions of dollars to train geriatricians; the Federal Trade Commission has opened an investigation into Teva Pharmaceuticals after the company refused to take down patents for its asthma and chronic obstructive pulmonary disease inhalers.

Matthew Callister, MD, Banner Health, discusses the advantage of value-based oncology care as a platform for collaboration.

Quality of life was also a top concern among patients when asked about their priorities if they experienced relapse or were refractory to therapy.

Experts urge enhanced monitoring as avian influenza spreads beyond birds; emergency abortion access still in legal limbo; leaders call for federal probe into potential misuse of health insurance subsidies.

Douglas Weber, MD, explains how zuranolone has changed the landscape for postpartum depression treatment, addressing a gap in care within maternal health.

For patients with paroxysmal nocturnal hemoglobinuria (PNH), crovalimab has emerged as an additional treatment option with a similar safety and efficacy profile to eculizumab,

Researchers review the latest developments, challenges, and ongoing research in posttransplant maintenance for acute myeloid leukemia (AML).

New findings show a similar number of injective-related reactions (IRRs) were reported between the use of ofatumumab (Kesimpta) and ocrelizumab (Ocrevus) in the treatment of multiple sclerosis, but less severe reactions have been associated with ofatumumab.

Charlie Borowicz, manager of trans and gender diverse health at Allegheny Health Network, shares how the program offers comprehensive patient-first care to those in the LGBTQ+ and gender diverse community.

Results from a cross-sectional study revealed the gaps in knowledge related to fertility risks among patients with sickle cell disease (SCD), as well as shed light on patient perspectives on fertility treatments.

However, registry data also showed no significant difference in transplant-free survival and time to pulmonary function decline between patients receiving antifibrotics vs placebo.

In this interview from our coverage of the European Hematology Association 2024 Congress, Joseph Mikhael, MD, MEd, FRCPC, FACP, International Myeloma Foundation, discusses the complex principles that underlie treating multiple myeloma (MM) in the US.

This new report reveals that the US has made minimal progress in advancing health care equity over the past 2 decades.